SWKH Profile
SWK Holdings Corporation is a specialty finance company with a focus on the healthcare and life sciences sectors. The company operates through two primary segments: Finance Receivables and Pharmaceutical Development. In the Finance Receivables segment, SWK Holdings offers bespoke financing solutions tailored to life science companies, including those in biotechnology, medical devices, diagnostics, animal health, and pharmaceuticals. This includes providing capital to support innovation and growth within these sectors, as well as offering financial solutions to institutions and inventors engaged in these industries.
SWK Holdings extends its services to institutional clients through non-discretionary investment advisory services. The company manages separately managed accounts that invest in life science finance, aiming to generate returns from investments in high-growth life science ventures. This advisory service is designed to provide tailored investment strategies and access to opportunities within the life sciences domain, leveraging the company's deep industry expertise.
In addition to its financing activities, SWK Holdings is actively involved in pharmaceutical development through its Peptelligence platform. This platform focuses on the development, formulation, manufacturing, and licensing of innovative pharmaceutical products. Among its product pipeline is Ovarest, an oral leuprolide tablet designed to treat endocrine diseases. This illustrates the company's commitment to advancing pharmaceutical innovations and bringing new therapies to market.
Originally known as Kana Software, Inc., SWK Holdings Corporation rebranded in December 2009 to reflect its strategic shift towards healthcare and life sciences finance. Established in 1996 and headquartered in Dallas, Texas, SWK Holdings continues to leverage its extensive experience and expertise to drive growth and innovation within the healthcare sector.
|
